Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy

Annals of Surgical Oncology

Volumn 16, Issue 7, 2009, Pages 1860-1867

  Nikfarjam, Mehrdad ^a   Shereef, Serene ^a   Kimchi, Eric T ^a   Gusani, Niraj J ^a   Jiang, Yixing ^a   Avella, Diego M ^a   Mahraj, Rickhesvar P ^a   Staveley O'Carroll, Kevin F ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; OXALIPLATIN;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; LENGTH OF STAY; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE CARE; PROGNOSIS; RADIOFREQUENCY ABLATION; SURGEON; SURGICAL MORTALITY; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CATHETER ABLATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 67649229489     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0225-3     Document Type: Article

References (24)

1. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77:1241-6.
2. Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg. 1984;199:502-8.
3. Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist. 2005;10 Suppl 3:40-8.
4. Khatri VP, Chee KG, Petrelli NJ. Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg Oncol. 2007;16:71-83.
5. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
6. Maindrault-Goebel F, Tournigand C, Andre T, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol. 2004;15:1210-4.
7. Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. Oncologist. 2007;12:825-39.
8. Scheele J, Altendorf-Hofmann A, Geoghegan JG, et al. Resection of colorectal liver metastases Treatment of colorectal liver metastases. Langenbecks Arch Surg. 1999;384:313-27.
9. Curley SA. Outcomes after surgical treatment of colorectal cancer liver metastases. Semin Oncol. 2005;32:S109-11.
10. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-18; discussion 318-21.
11. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247: 125-35.
12. de Jong KP. Review article: multimodality treatment of liver metastases increases suitability for surgical treatment. Aliment Pharmacol Ther. 2007;26 Suppl 2:161-9.
13. Adam R, Aloia T, Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007; 25:4593-602.
14. Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan- European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212-21.
15. Wicherts DA, de Haas RJ, Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol. 2007; 33 Suppl 2:S42-51.
16. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-57; discussion 657-648.
17. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254-62.
18. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-16.
19. Adam R, Lucidi V, Bismuth H. Hepatic colorectal metastases: methods of improving resectability. Surg Clin North Am. 2004; 84:659-71.
20. Capussotti L, Muratore A, Mulas MM, et al. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg. 2006;93:1001-6.
21. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10:663-9.
22. Mitry E, Fields A, Bleiberg H. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. ASCO Annual Meeting Proceedings. J Clin Oncol. 2006;24:152 s.
23. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976-82.
24. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938-46.